3) Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 ; 581 : 465-9. PMID : 32235945
5) Zhan M, Qin Y, Xue X, et al. Death from Covid-19 of 23 health care workers in China. N Engl J Med. 2020 ; 382 : 2267-8. PMID : 32294342
8) https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
9) https://www.idsociety.org/globalassets/idsa/public-health/covid-19-prioritization-ofdx-testing.pdf
11) 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第6.2版「一類感染症等の患者発生時に備えた臨床的対応に関する研究」 (厚生労働行政推進調査事業費補助金 新興・再興感染症及び予防接種政策推進研究事業). https://www.mhlw.go.jp/content/000888565.pdf (2022年1月15日閲覧)
12) 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 第4.1版. https://www.mhlw.go.jp/content/000841541.pdf
14) Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020 ; 323 : 2052-9. PMID : 32320003
16) Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020 ; 295 : 715-21. PMID : 32053470
18) Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia : ARDS or not? Crit Care. 2020 ; 24 : 154. PMID : 32299472
19) 岩田健太郎. 丁寧に考える新型コロナ. 東京 : 光文社 ; 2020.
20) Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 ; 382 : 1199-207. PMID : 31995857
21) US CDC. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19 : Information for Healthcare Providers. Oct 14 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (2022年2月7日閲覧)
23) NIH COVID-19 Treatment Guidelines. Therapeutic Management of Hospitalized Adults With COVID-19 (16 Dec 2021 最終更新) https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/
25) Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021 ; 385 : e81. PMID : 34587383
27) Wilhelm A, Marek Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv preprint doi : https://doi.org/10.1101/2021.12.07.21267432 ; this version posted December 8, 2021
29) FDA Emergency Use Authorization. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COV(R) (casirivimab and imdevimab). https://www.fda.gov/media/145611/download
30) FDA Emergency Use Authorization. FACT SHEET FOR HEALTHCARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF SOTROVIMAB. https://www.fda.gov/media/149534/download
33) https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (Accessed on November 05, 2021).
37) Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : a randomized clinical trial. JAMA. 2020 ; 324 : 1048-57. PMID : 32821939
39) Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy) : a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022 ; 22 : 209-21. PMID : 34534511
41) Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021 ; 384 : 795-807. PMID : 33306283
42) Dunay MA, McClain SL, Holloway RL, et al. Pre-hospital administration of remdesivir during a SARS-CoV-2 outbreak in a skilled nursing facility. Clin Infect Dis. 2021 Aug 19 ; ciab715. PMID : 34410348
44) Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020 Apr 27 ; ciaa478. PMID : 32338708 https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v6.0.1.pdf
48) COVID STEROID 2 Trial Group, Munch MW, Myatra SN, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia : the COVID STEROID 2 randomized trial. JAMA. 2021 ; 326 : 1807-17. PMID : 34673895
49) Dunay MA, McClain SL, Holloway RL, et al. Pre-hospital administration of remdesivir during a SARS-CoV-2 outbreak in a skilled nursing facility. Clin Infect Dis. 2021 Aug 19 ; ciab715. PMID : 34410348
54) 日本集中治療学会・日本救急医学会. 日本版敗血症診療ガイドライン 2020 (J-SSCG2020) 特別編 COVID-19 薬物療法に関するRapid/Living recommendations 第4.1版. https://www.jsicm.org/news/J-SSCG2020_COVID19.html
55) Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 ; 9 : 1407-18. PMID : 34480861
57) RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial. Lancet. 2021 ; 397 : 1637-45. PMID : 33933206
60) Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020 ; 383 : 2333-44. PMID : 33085857
64) NIH Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/
67) Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 ; 64 : e01897-20. PMID : 32958718
73) NIHTreatment Guidelines- Ivermectin. https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/